Associations of metabolic phenotypes with cardiac structure, and clinical outcomes: insights from the UK Biobank.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 41428372.
- Also identified by DOI 10.1210/clinem/dgaf684.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Metabolic syndrome and obesity represent major cardiovascular risk factors, yet their combined effects on cardiac structure and clinical outcomes remain incompletely understood. To examine associations between metabolic phenotypes, cardiac magnetic resonance imaging (CMR) and clinical outcomes. Prospective study with a median 5.1-year follow-up. Population-based cohort from the UK Biobank. 22,789 participants (mean age 64.1±7.5 years, 52.6% female) were categorized as metabolically healthy non-obese (MHN) vs. obese (MHO), unhealthy non-obese (MUN) vs. obese (MUO), based on obesity (BMI ≥30 kg/m²), and metabolic status (prevalent diabetes or both hypertension and hyperlipidemia). Primary and secondary endpoints were major adverse cardiovascular events (MACE) and all-cause mortality, respectively. CMR included left ventricular ejection fraction (LVEF, %), end-diastolic volume (LVEDV, mL), myocardial mass (LVM, g), wall thickness (WT, mm), cardiac output (CO, L/min), and left atrial volume (LAV, mL). Linear regression and Cox proportional hazards models, adjusted for age, sex, and smoking, assessed associations between metabolic phenotypes, CMR, and clinical outcomes. In adjusted models, all phenotypes demonstrated increased WT (MHO: β=0.53 [0.50, 0.55]; MUN: β=0.24 [0.21, 0.27]; MUO: β=0.66 [0.61, 0.70]), compared to MHN. LVEDV was increased in obesity phenotypes (MHO: β=4.67 [4.07, 5.27]; MUO: β=5.14 [4.05, 6.22]), and decreased in MUN (β=-1.25 [-1.95, -0.55]), while MUO showed reduced LVEF (β=-0.48 [-0.91, -0.04]). MACE risk was increased in unhealthy phenotypes (MUN: aHR=1.55 [1.16-2.07]; MUO: aHR=1.95 [1.28-2.97]). All phenotypes showed increased all-cause mortality risk (MHO: aHR=1.65 [1.23-2.21]; MUN: aHR=1.41 [1.05-1.90]; MUO: 2.10 [1.41-3.15]). Metabolic phenotypes show distinct cardiac structural changes and increased mortality risk, supporting their potential in cardiovascular risk stratification.